SML1931

SLV320

≥98% (HPLC)

• 同義詞: 4-[(4-trans-Hydroxycyclohexyl)amino]-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine, Derenofylline, SLV 320, SLV-320, trans-4-[(2-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexanol
• 經驗公式（希爾表示法）: C₁₈H₂₀N₄O
• CAS號碼: 251945-92-3
• 分子量：: 308.38
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: O[C@H]1CC[C@@H](CC1)NC2=NC(C3=CC=CC=C3)=NC4=C2C=CN4
• InChI: 1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)
• InChI 密鑰: RBZNJGHIKXAKQE-UHFFFAOYSA-N

描述

生化／生理作用

Orally active, high-affinity adenosine receptor A1-selective antagonist with in vitro and in vivo efficacy.

SLV320 is an orally active, high-affinity adenosine receptor A1 antagonist (pKi = 9.0 against 3H-DPCPX for binding human A1R and 8.6 against 3H-CCPA for binding rat A1R) that exhibits higher A1R-selectivity than DPCPX over other adenosine receptor subtypes (Fold-selectivity/subtypes = 200/hA3, 398/hA2a, 3981/hA2b). SLV320 displays much reduced or little affinity toward a panel of 94 other receptors and no inhibitory activity against PDE1-6 (IC50 ≥1 μM). SLV320 selectively reduces A1R-mediated bradycardia (ED50 = 0.49 mg/kg via p.o. or 0.25 mg/kg via i.v. 10 min prior to 100 μg/kg adenosine i.v. challenge), but not A2R-dependent hypotension (up to 2 mg/kg) among adenosin-challenged rats. When administered via food intake, SLV320 efficacy is demonstrated in experimental models of chronic renal failure (CRF; 10 mg/kg/day) and liver cirrhosis (5.1 mg/kg/day p.o.) in rats in vivo.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable